Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain Management | 4 | 2021 | 179 | 1.050 |
Why?
|
| Hyperthermia, Induced | 2 | 2022 | 75 | 0.780 |
Why?
|
| Analgesics, Opioid | 5 | 2021 | 513 | 0.740 |
Why?
|
| Cachexia | 1 | 2020 | 14 | 0.640 |
Why?
|
| Anorexia | 1 | 2020 | 28 | 0.640 |
Why?
|
| Cancer Pain | 1 | 2019 | 5 | 0.610 |
Why?
|
| Appendiceal Neoplasms | 1 | 2019 | 37 | 0.610 |
Why?
|
| Constipation | 1 | 2020 | 69 | 0.600 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 154 | 0.570 |
Why?
|
| Nausea | 1 | 2020 | 182 | 0.570 |
Why?
|
| Vomiting | 1 | 2020 | 201 | 0.560 |
Why?
|
| Chronic Pain | 2 | 2016 | 186 | 0.460 |
Why?
|
| Palliative Care | 4 | 2023 | 273 | 0.390 |
Why?
|
| Neoplasms | 4 | 2021 | 3250 | 0.370 |
Why?
|
| Pain Measurement | 3 | 2019 | 378 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 647 | 0.330 |
Why?
|
| Dementia | 2 | 2020 | 218 | 0.250 |
Why?
|
| Quality of Life | 4 | 2022 | 1816 | 0.220 |
Why?
|
| Surgical Oncology | 1 | 2023 | 29 | 0.200 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2022 | 92 | 0.200 |
Why?
|
| Spiritual Therapies | 1 | 2021 | 4 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 1 | 2022 | 193 | 0.170 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 1773 | 0.160 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2020 | 25 | 0.160 |
Why?
|
| Mitomycin | 1 | 2019 | 29 | 0.160 |
Why?
|
| Terminal Care | 1 | 2021 | 146 | 0.150 |
Why?
|
| Physical Examination | 1 | 2020 | 154 | 0.150 |
Why?
|
| Nerve Block | 1 | 2019 | 52 | 0.150 |
Why?
|
| Delirium | 1 | 2019 | 79 | 0.140 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 189 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 192 | 0.140 |
Why?
|
| Advance Care Planning | 1 | 2018 | 44 | 0.130 |
Why?
|
| Humans | 15 | 2023 | 96127 | 0.130 |
Why?
|
| Critical Illness | 1 | 2020 | 346 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 169 | 0.130 |
Why?
|
| Low Back Pain | 1 | 2016 | 59 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2019 | 408 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1973 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2018 | 1546 | 0.110 |
Why?
|
| Students, Medical | 1 | 2020 | 455 | 0.110 |
Why?
|
| Administration, Topical | 1 | 2014 | 86 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2014 | 61 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 1069 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 2014 | 133 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1068 | 0.100 |
Why?
|
| Analgesics | 1 | 2014 | 132 | 0.100 |
Why?
|
| Myokymia | 1 | 2013 | 4 | 0.100 |
Why?
|
| Biomarkers | 1 | 2020 | 1933 | 0.100 |
Why?
|
| Thymoma | 1 | 2013 | 33 | 0.100 |
Why?
|
| Neuralgia | 1 | 2013 | 33 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 249 | 0.100 |
Why?
|
| Thymus Neoplasms | 1 | 2013 | 47 | 0.090 |
Why?
|
| Aged | 5 | 2019 | 20964 | 0.090 |
Why?
|
| Video Recording | 1 | 2013 | 214 | 0.090 |
Why?
|
| Prognosis | 3 | 2018 | 4033 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 7232 | 0.080 |
Why?
|
| Algorithms | 1 | 2018 | 2014 | 0.080 |
Why?
|
| Pain | 2 | 2021 | 426 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1096 | 0.070 |
Why?
|
| Female | 8 | 2023 | 50063 | 0.060 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2023 | 10286 | 0.050 |
Why?
|
| Male | 6 | 2021 | 45870 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 52 | 0.040 |
Why?
|
| Middle Aged | 6 | 2023 | 28363 | 0.040 |
Why?
|
| Survival Rate | 2 | 2022 | 1986 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 901 | 0.040 |
Why?
|
| Problem-Based Learning | 1 | 2020 | 40 | 0.040 |
Why?
|
| Spirituality | 1 | 2021 | 87 | 0.040 |
Why?
|
| Death | 1 | 2021 | 97 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 1996 | 855 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 456 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 3107 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2016 | 136 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 615 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 3927 | 0.030 |
Why?
|
| Adult | 4 | 2023 | 28718 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1994 | 89 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1996 | 286 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 1503 | 0.020 |
Why?
|
| Decision Making | 1 | 2018 | 694 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2642 | 0.020 |
Why?
|
| Electromyography | 1 | 2013 | 201 | 0.020 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2013 | 127 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 357 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 483 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 9173 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 1996 | 44 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1996 | 482 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1994 | 58 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 769 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1996 | 1010 | 0.010 |
Why?
|
| Cell Division | 1 | 1994 | 705 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 1054 | 0.010 |
Why?
|
| Adolescent | 2 | 1996 | 9896 | 0.010 |
Why?
|
| Disease Progression | 1 | 1994 | 1568 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1994 | 1469 | 0.000 |
Why?
|
| Infant | 1 | 1994 | 3363 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1994 | 3974 | 0.000 |
Why?
|
| Child | 1 | 1994 | 7626 | 0.000 |
Why?
|